Vakharia Kunal, Munich Stephan A, Waqas Muhammad, McPheeters Matthew J, Levy Elad I
Department of Neurosurgery, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York.
Department of Neurosurgery, Gates Vascular Institute at Kaleida Health, Buffalo, New York.
Oper Neurosurg (Hagerstown). 2020 Jun 1;18(6):E230-E231. doi: 10.1093/ons/opz251.
Flow diversion using a Pipeline embolization device (PED; Medtronic, Dublin, Ireland) is an effective therapy for treating cavernous aneurysms. Currently, flow diverters require a 0.027-inch microcatheter for deployment. To navigate across these aneurysms, a 0.014-inch microwire is used, which often does not offer a sturdy enough rail to advance a 0.027-inch microcatheter past dissecting artery aneurysm ostia. We present a patient with a right cavernous dissecting carotid artery aneurysm. A step off between the 0.027-inch VIA microcatheter (MicroVention Terumo, Tustin, California) and 0.014-inch Synchro 2 microwire (Stryker Neurovascular, Fremont, California) resulted in difficulty with navigation of the microcatheter across the dissected portion of the aneurysm. A dual microwire rail technique involving two 0.014-inch Synchro 2 microwires was used to advance the VIA microcatheter past the dissecting artery aneurysm ostia for PED deployment. The introduction of the second microwire eliminated the step off between the microwire and microcatheter, providing a stronger rail and easier navigation of the microcatheter, without aggressive pushing. Postembolization runs showed optimal wall apposition and contrast stasis within the aneurysm, with successful flow diversion of the aneurysm. The patient gave informed consent for surgery and video recording. Institutional review board approval was deemed unnecessary.
使用管道栓塞装置(PED;美敦力公司,爱尔兰都柏林)进行血流导向是治疗海绵状动脉瘤的一种有效疗法。目前,血流导向装置需要使用0.027英寸的微导管进行部署。为了穿过这些动脉瘤,会使用0.014英寸的微导丝,但它通常无法提供足够坚固的轨道来推动0.027英寸的微导管越过夹层动脉瘤开口处。我们报告了一名患有右侧海绵窦段颈内动脉夹层动脉瘤的患者。0.027英寸的VIA微导管(MicroVention Terumo公司,加利福尼亚州图斯廷)与0.014英寸的Synchro 2微导丝(史赛克神经血管公司,加利福尼亚州弗里蒙特)之间的落差导致微导管难以穿过动脉瘤的夹层部分。采用了一种双微导丝轨道技术,即使用两根0.014英寸的Synchro 2微导丝,以推动VIA微导管越过夹层动脉瘤开口处,以便进行PED部署。第二根微导丝的引入消除了微导丝与微导管之间的落差,提供了更强的轨道,使微导管更容易操控,无需用力推送。栓塞术后造影显示动脉瘤内有最佳的壁贴合和造影剂滞留,动脉瘤实现了成功的血流导向。患者已签署手术及录像知情同意书。机构审查委员会批准被认为不必要。